Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON55125
NL-OMON55125
Completed
Phase 2

Study on the Safety, Tolerability and Efficacy of the Aqua Medical focal vapor ablation system, for the eradication of Barrett*s Esophagus - part 2 - The STEAM-BE study 2

Academisch Medisch Centrum0 sites28 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsEsophageal CarcinomaIntestinal Metaplasia1001799010017991

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Esophageal Carcinoma
Sponsor
Academisch Medisch Centrum
Enrollment
28
Status
Completed
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Adult patients with Barrett esophagus and early neoplasia, with an indication
  • •for endoscopic treatment

Exclusion Criteria

  • •Patients with prior ablation therapy or contra\-indications for ablation
  • •therapy. Subjects with any condition that in the opinion of the PI preclude
  • •enrollment into the trial,

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Not Applicable
Study on the Safety, Tolerability and Efficacy of the Aqua Medical focal vapor ablation system, for the eradication of Barrett's Esophagus - part 2
NL-OMON20279Aqua Medical, Inc.19
Not yet recruiting
Not Applicable
Soft capsules with ozonated sunflower oil versus oral OLEOZON® in patients with GiardiosisGiardiosis
RPCEC00000440ational Centre for Scientific Research (CNIC)200
Not yet recruiting
Phase 3
Abexol (suspension) versus Abexol (tablets) in patients with gastrointestinal symptomsGastrointestinal symptomsSigns and Symptoms, DigestiveDigestive System Diseases
RPCEC00000372ational Centre for Scientific Research100
Active, not recruiting
Phase 1
Phase 2b study evaluating efficacy, safety and tolerability of study drug called NGM282 (Aldafermin) in Patients with Compensated Cirrhosis Due to Nonalcoholic SteatohepatitisCompensated Cirrhosis Due to Nonalcoholic SteatohepatitisMedDRA version: 22.0Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersMedDRA version: 20.1Level: LLTClassification code 10064844Term: Compensated cirrhosisSystem Organ Class: 10019805 - Hepatobiliary disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
EUCTR2019-002341-38-FRGM Biopharmaceuticals, Inc.150
Completed
Not Applicable
study on low back pai
CTRI/2016/10/007348Dr Reddys Laboratories Pvt Ltd